BSE’s Department of Surveillance (DOSS) has revised price bands for 21 equity scrips, effective May 4, 2026. The revised bands range from 2% to 20%, replacing the existing levels for each scrip. This is a routine surveillance action aimed at curbing excessive volatility or speculative activity in select securities.

Key Points

• Price bands revised for 21 scrips across equity segment, effective May 4, 2026.
• Revised bands: 2% (2 scrips), 5% (12 scrips), 10% (2 scrips), 20% (5 scrips).
• Action taken by BSE Surveillance department (DOSS).
• Members may seek clarification at bse.surv@bseindia.com.

Revised Price Bands

Regulatory Changes

Price bands are revised by BSE Surveillance as a measure to control abnormal price movements. A tightened band (e.g., 2% or 5%) restricts daily price movement, while a wider band (e.g., 20%) allows greater fluctuation. These revisions supersede previously applicable bands for the listed scrips.

Compliance Requirements

Trading members must note and apply the revised price bands for the affected scrips starting May 4, 2026. No action is required beyond awareness; the exchange systems will enforce the new limits automatically. Members with queries may contact bse.surv@bseindia.com.

Important Dates

• Notice Date: April 30, 2026
• Effective Date: May 4, 2026

Impact Assessment

Traders and investors holding positions in any of the 21 affected scrips should be aware of the new daily price movement limits. Scrips assigned a 2% band (Emrock Corporation, iStreet Network) face the most restrictive limits, potentially reducing liquidity. The 5 scrips assigned a 20% band (Clinitech Laboratory, Om Power Transmission, Prima Plastics, Transgene Biotek, and Clinitech Laboratory) have relatively wider movement permitted. Overall market impact is limited to these specific securities; broader indices are unaffected.